Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | ESR2 | Q92731 | 7/20 | 0.41 |
| ▸ | ESR1 | P03372 | 6/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | GBA1 | P04062 | 2/20 | 0.32 |
| ▸ | APLNR | P35414 | 1/20 | 0.32 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6773661 | 0.95 | TSHR (0.45) | TSHRESR2ESR1CYP3A4CYP2C9 | |
| SCHEMBL17785971 | 0.94 | TSHR (0.50) | TSHRESR2ESR1CYP3A4CYP2C9 | |
| Cyclohexanol SCHEMBL25424646 | 0.92 | TSHR (0.56) | TSHRESR2ESR1CYP3A4CYP2C9 | |
| SCHEMBL6783213 | 0.89 | TSHR (0.53) | TSHRESR2ESR1CYP3A4CYP2C9 | |
| SCHEMBL5461 | 0.87 | — | — | |
| SCHEMBL2936955 | 0.87 | ESR2 (0.46) | ESR2ESR1CYP3A4CYP2C9CYP2D6 | |
| SCHEMBL6562400 | 0.84 | ESR2 (0.50) | ESR2ESR1CYP3A4CYP2C9CYP2D6 | |
| Hydrochloric Acid SCHEMBL20579190 | 0.84 | — | — | |
| Water SCHEMBL28134785 | 0.84 | — | — | |
| Ammonia Solution, Strong SCHEMBL8055914 | 0.84 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6673920-B2 | REACTING AMIDES WITH ACETYLENES IN THE LIQUID PHASE IN THE PRESENCE OF BASIC ALKALI METAL COMPOUNDS AND OF A COCATALYST, WHICH COMPRISES USING AS THE COCATALYST DIOLS TO PREPARE N-ALKENYL-AMIDE | BASF AKTIENGESELLSCHAFT (DE) | 2004-01-06 | — | — | US | disclosed |
| US-20030036659-A1 | Method for the production of n-alkenyl amides | BASF AKTIENGESELLSCHAFT (DE) | 2003-02-20 | — | — | US | disclosed |
| EP-1240140-A1 | METHOD FOR THE PRODUCTION OF N-ALKENYL AMIDES | BASF AKTIENGESELLSCHAFT (DE) | 2002-09-18 | — | — | EP | disclosed |
| WO-2001046141-A1 | METHOD FOR THE PRODUCTION OF N-ALKENYL AMIDES | BASF AKTIENGESELLSCHAFT (DE) | 2001-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030036659-A1 | Method for the production of n-alkenyl amides | NAT1, SAT1, AGPAT2 | TSHR 3194/4885ESR2 3104/4885ESR1 3675/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.